Logo image of CYRX

CRYOPORT INC (CYRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CYRX - US2290503075 - Common Stock

9.6 USD
-0.04 (-0.41%)
Last: 12/31/2025, 8:00:01 PM
9.79 USD
+0.19 (+1.98%)
After Hours: 12/31/2025, 8:00:01 PM
Fundamental Rating

4

CYRX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. While CYRX seems to be doing ok healthwise, there are quite some concerns on its profitability. CYRX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year CYRX was profitable.
In the past year CYRX has reported a negative cash flow from operations.
CYRX had negative earnings in each of the past 5 years.
In the past 5 years CYRX reported 4 times negative operating cash flow.
CYRX Yearly Net Income VS EBIT VS OCF VS FCFCYRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of 7.69%, CYRX belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
The Return On Equity of CYRX (11.61%) is better than 84.21% of its industry peers.
Industry RankSector Rank
ROA 7.69%
ROE 11.61%
ROIC N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
CYRX Yearly ROA, ROE, ROICCYRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

Looking at the Profit Margin, with a value of 31.31%, CYRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
With a Gross Margin value of 46.58%, CYRX perfoms like the industry average, outperforming 47.37% of the companies in the same industry.
CYRX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 31.31%
GM 46.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
CYRX Yearly Profit, Operating, Gross MarginsCYRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

4

2. Health

2.1 Basic Checks

CYRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CYRX has more shares outstanding
Compared to 5 years ago, CYRX has more shares outstanding
CYRX has a better debt/assets ratio than last year.
CYRX Yearly Shares OutstandingCYRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CYRX Yearly Total Debt VS Total AssetsCYRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 0.66, we must say that CYRX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CYRX (0.66) is worse than 66.67% of its industry peers.
A Debt/Equity ratio of 0.36 indicates that CYRX is not too dependend on debt financing.
CYRX has a Debt to Equity ratio (0.36) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z 0.66
ROIC/WACCN/A
WACC8.98%
CYRX Yearly LT Debt VS Equity VS FCFCYRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 15.77 indicates that CYRX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 15.77, CYRX belongs to the best of the industry, outperforming 98.25% of the companies in the same industry.
A Quick Ratio of 15.01 indicates that CYRX has no problem at all paying its short term obligations.
CYRX's Quick ratio of 15.01 is amongst the best of the industry. CYRX outperforms 98.25% of its industry peers.
Industry RankSector Rank
Current Ratio 15.77
Quick Ratio 15.01
CYRX Yearly Current Assets VS Current LiabilitesCYRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 157.07% over the past year.
The Revenue for CYRX has decreased by -15.86% in the past year. This is quite bad
Measured over the past years, CYRX shows a very strong growth in Revenue. The Revenue has been growing by 46.45% on average per year.
EPS 1Y (TTM)157.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
Revenue 1Y (TTM)-15.86%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-21.94%

3.2 Future

The Earnings Per Share is expected to grow by 13.21% on average over the next years. This is quite good.
Based on estimates for the next years, CYRX will show a small growth in Revenue. The Revenue will grow by 0.88% on average per year.
EPS Next Y220.55%
EPS Next 2Y18.08%
EPS Next 3Y13.9%
EPS Next 5Y13.21%
Revenue Next Year-24%
Revenue Next 2Y-8.87%
Revenue Next 3Y-3.1%
Revenue Next 5Y0.88%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CYRX Yearly Revenue VS EstimatesCYRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
CYRX Yearly EPS VS EstimatesCYRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 -1 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 8.21, which indicates a very decent valuation of CYRX.
Compared to the rest of the industry, the Price/Earnings ratio of CYRX indicates a rather cheap valuation: CYRX is cheaper than 100.00% of the companies listed in the same industry.
CYRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.51.
The Forward Price/Earnings Ratio is negative for CYRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 8.21
Fwd PE N/A
CYRX Price Earnings VS Forward Price EarningsCYRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYRX Per share dataCYRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

CYRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CYRX's earnings are expected to grow with 13.90% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y18.08%
EPS Next 3Y13.9%

More info and screens

0

5. Dividend

5.1 Amount

CYRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CRYOPORT INC

NASDAQ:CYRX (12/31/2025, 8:00:01 PM)

After market: 9.79 +0.19 (+1.98%)

9.6

-0.04 (-0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners102.73%
Inst Owner Change3.12%
Ins Owners4.01%
Ins Owner Change9.37%
Market Cap480.67M
Revenue(TTM)190.26M
Net Income(TTM)59.58M
Analysts85.33
Price Target13.49 (40.52%)
Short Float %6.38%
Short Ratio4.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)486.84%
Min EPS beat(2)16.41%
Max EPS beat(2)957.28%
EPS beat(4)3
Avg EPS beat(4)236.36%
Min EPS beat(4)-40.53%
Max EPS beat(4)957.28%
EPS beat(8)5
Avg EPS beat(8)88.31%
EPS beat(12)7
Avg EPS beat(12)52.28%
EPS beat(16)8
Avg EPS beat(16)33.95%
Revenue beat(2)2
Avg Revenue beat(2)5.82%
Min Revenue beat(2)4.86%
Max Revenue beat(2)6.79%
Revenue beat(4)2
Avg Revenue beat(4)1.51%
Min Revenue beat(4)-5.29%
Max Revenue beat(4)6.79%
Revenue beat(8)2
Avg Revenue beat(8)-1.64%
Revenue beat(12)3
Avg Revenue beat(12)-1.56%
Revenue beat(16)3
Avg Revenue beat(16)-2.77%
PT rev (1m)0%
PT rev (3m)9.17%
EPS NQ rev (1m)-3.28%
EPS NQ rev (3m)-7.94%
EPS NY rev (1m)673.83%
EPS NY rev (3m)739.16%
Revenue NQ rev (1m)-0.38%
Revenue NQ rev (3m)-0.71%
Revenue NY rev (1m)1.07%
Revenue NY rev (3m)1.24%
Valuation
Industry RankSector Rank
PE 8.21
Fwd PE N/A
P/S 2.53
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 1.37
EV/EBITDA N/A
EPS(TTM)1.17
EY12.19%
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS3.8
BVpS10.25
TBVpS6.98
PEG (NY)0.04
PEG (5Y)N/A
Graham Number16.43
Profitability
Industry RankSector Rank
ROA 7.69%
ROE 11.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 31.31%
GM 46.58%
FCFM N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
F-Score6
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 69.06%
Cap/Sales 10.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.77
Quick Ratio 15.01
Altman-Z 0.66
F-Score6
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)112.93%
Cap/Depr(5y)112.05%
Cap/Sales(3y)12.92%
Cap/Sales(5y)12.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)157.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
EPS Next Y220.55%
EPS Next 2Y18.08%
EPS Next 3Y13.9%
EPS Next 5Y13.21%
Revenue 1Y (TTM)-15.86%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-21.94%
Revenue Next Year-24%
Revenue Next 2Y-8.87%
Revenue Next 3Y-3.1%
Revenue Next 5Y0.88%
EBIT growth 1Y44.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year96.51%
EBIT Next 3Y29.15%
EBIT Next 5Y18.96%
FCF growth 1Y13.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3666.43%
OCF growth 3YN/A
OCF growth 5YN/A

CRYOPORT INC / CYRX FAQ

What is the ChartMill fundamental rating of CRYOPORT INC (CYRX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CYRX.


Can you provide the valuation status for CRYOPORT INC?

ChartMill assigns a valuation rating of 4 / 10 to CRYOPORT INC (CYRX). This can be considered as Fairly Valued.


What is the profitability of CYRX stock?

CRYOPORT INC (CYRX) has a profitability rating of 3 / 10.


What are the PE and PB ratios of CRYOPORT INC (CYRX) stock?

The Price/Earnings (PE) ratio for CRYOPORT INC (CYRX) is 8.21 and the Price/Book (PB) ratio is 0.94.


How financially healthy is CRYOPORT INC?

The financial health rating of CRYOPORT INC (CYRX) is 4 / 10.